Carotid Stents Used In NIH CREST Trial Could Receive HCFA Reimbursement
This article was originally published in The Gray Sheet
Executive Summary
Stent-assisted carotid percutaneous angioplasty procedures (SACPTA) performed as part of the NIH-funded Carotid Revascularization Endarterectomy v. Stenting (CREST) trial could be reimbursed under Medicare provided preliminary data shows favorable outcomes.
You may also be interested in...
Bard R&D To Triple In Three Years Through Savings From Plant Consolidation
Consolidation of C.R. Bard manufacturing and non-manufacturing facilities over the next three years is expected to save the firm up to $70 mil. annually and allow the firm to roughly triple its R&D budget to about $150 mil. by 2004.
Japan Regulatory Update: Revised Law Widens RWD Scope, Price Revisions/Listings
Japan now allows pseudonymized personal data for medical use under a licensing system for wider use of real-world data. Meanwhile, a national cost-effectiveness assessment scheme has slashed reimbursement prices for Lagevrio and Kerendia, and Alexion’s Voydeya has been added to the reimbursement tariff.